Ann: Immutep Investor Update, page-26

Whilst I concur with both the above, I referenced this section of the Jan 2019 update: 


AIPAC Clinical Study – Phase IIbRecruitment of patients for our Phase II AIPAC trial is progressing well. We are pleased to report that as of the middle of January 2019, 179 patients have been recruited to the trial, almost 80% of our 226-patient target. Recruitment will continue. We are on schedule to report the first progression free survival (PFS) data from trial in H2 2019.

I used the term "endpoint" erroneously. I should have said PFS.

There are at least 5 months in hand to finalise recruitment and treatment for a result to be compiled by June.
That would be a very tight deadline, and I'm by no means sure that it's achievable.
My point was simply that, given the relative proximity, I'm not expecting an interim result announcement.

It might be a bonus, were it to come out (hopefully positive) in time for release at ASCO (May 31 - June 4).

.